Introducing the only kennel cough vaccine you can give orally.
Bronchi-Shield® Oral.
Explore the Bronchi-Shield® ORAL Challenge Study
Bronchi-Shield® ORAL Product Questions
What is BRONCHI-SHIELD ORAL?
BRONCHI-SHIELD ORAL is a unique Canine Infectious Respiratory Disease (CIRD) vaccine because it is the first modified live, avirulent Bordetella bronchiseptica vaccine licensed to be administered orally to dogs. It’s easy to administer for mucosal absorption and has been proven effective in a published, peer-reviewed challenge study.*
Why does BRONCHI-SHIELD ORAL only contain Bordetella bronchiseptica?
It is well established that Bordetella bronchiseptica is the primary pathogen for CIRD. For high-population facilities, protection against Bordetella bronchiseptica is of primary importance in the control of CIRD.
Is Bordetella bronchiseptica in BRONCHI-SHIELD ORAL the same as BRONCHI-SHIELD® III?
Both products contain the same organism at different titer levels. BRONCHI-SHIELD ORAL requires a higher titer of Bordetella bronchiseptica.
Should Veterinarians use BRONCHI-SHIELD III orally?
No. It is true BIVI has published data demonstrating the Bordetella bronchiseptica fraction of BRONCHI-SHIELD III protects when given orally. Veterinarians should know the minimum immunizing dose for oral efficacy is higher than the minimum immunizing dose for effective nasal administration. All serials of BRONCHI-SHIELD ORAL will have adequate antigen to protect orally. However, not all serials of BRONCHI-SHIELD III will meet the minimum immunizing dose standard for oral administration. Variances in BRONCHI-SHIELD III titers means veterinarians cannot depend on BRONCHI-SHIELD III for oral efficacy. In addition, there is no protection for the viral fractions of BRONCHI-SHIELD III when given orally.
How does BRONCHI-SHIELD ORAL work?
The study demonstrates the orally administered vaccine conveys protection against Bordetella bronchiseptica challenge. The study was not designed to explain the mode of action. However, when a vaccine is delivered through the nose or mouth, it ends up at the back of the throat, where immunological processing most likely occurs.
Is BRONCHI-SHIELD ORAL safe?
Yes. BRONCHI-SHIELD ORAL was licensed by USDA based on a field trial demonstrating safety by a nasal route of administration. Intranasal administration can expose both the nasal and oral cavities to the vaccine. Consequently, the safety of the oral vaccine is supported.
Is BRONCHI-SHIELD ORAL made with PureFil™ Technology?
Yes. PureFil Technology is BIVI’s ongoing commitment to quality and continuous improvement. BRONCHI-SHIELD ORAL is manufactured by BIVI using PureFil Technology, as are Duramune®, Fel-O-Vax® and Fel-O-Guard® brands.
BRONCHI-SHIELD ORAL Use
How is BRONCHI-SHIELD ORAL administered?
The vaccine cake is reconstituted with the supplied sterile water diluent and drawn into a syringe. Then, the needle is removed and 1 mL of vaccine is instilled into the buccal cavity. The vaccine is easy to administer and comfortable for the dog with no sneeze back.
What happens if BRONCHI-SHIELD ORAL is swallowed?
BRONCHI-SHIELD ORAL is designed to be instilled into the buccal cavity of the dog’s mouth. However, there is no concern if the dog swallows a small amount of BRONCHI-SHIELD ORAL, as this would be extremely difficult to prevent when administered. It’s likely some of the challenge study dogs swallowed the product and they were still protected in challenge.
Is BRONCHI-SHIELD ORAL palatable to dogs?
Made from culture media fluids, the vaccine was orally administered to more than 100 dogs at the University of Missouri Veterinary Teaching Hospital. Dogs readily accepted the vaccine, and there were no issues or adverse events.
How do I know BRONCHI-SHIELD ORAL is placed correctly in the mouth?
If the product is instilled anywhere in the buccal cavity (between the cheek and gum), it has been administered correctly.
Is the 1 mL dose of vaccine too much fluid for small dogs?
Any dog, large or small, can accommodate the 1 mL of fluid in its buccal cavity. For example, the dose of amoxicillin or liquid NSAID is about 1 mL for a dog less than 10 pounds.
Do veterinarians have to use the entire 1 mL of vaccine?
Yes. BRONCHI-SHIELD ORAL is labeled for a 1 mL dose based on efficacy against Bordetella bronchiseptica in a challenge study.
Can BRONCHI-SHIELD ORAL be given to young puppies?
BRONCHI-SHIELD ORAL is labeled to be given to puppies 8 weeks of age or older.
What is the recommended revaccination interval for BRONCHI-SHIELD ORAL?
The vaccine is labeled for annual revaccination which is consistent with the AAHA Canine Vaccine Guidelines.
Regardless of how I have given CIRD vaccines in the past, how easy will it be to transition canine patients to BRONCHI-SHIELD ORAL?
The vaccine is easy to administer and comfortable for the dog with no sneeze back. We also expect pet owners to appreciate fewer injections and less head restraint for their dog.
What happens if a veterinarian injects BRONCHI-SHIELD ORAL?
The veterinarian should call the VeTS team immediately and report the event at 866.638.2226.
BRONCHI-SHIELD ORAL and AAHA Canine Vaccine Guidelines
What do the AAHA Canine Vaccine Guidelines say about administering CIRD vaccines orally?
When the committee finalized the 2011 AAHA Canine Guidelines, neither BRONCHI-SHIELD ORAL nor any other oral respiratory vaccines were on the market. Consequently, there is no information in the guidelines on oral administration.
AAHA Canine Vaccine Guidelines recommend parainfluenza be given intranasally. What if someone chooses to stay with an intranasal option?
If this type of protection is important, BIVI offers two intranasal vaccines containing parainfluenza — BRONCHI-SHIELD III and Naramune-2TM.
Respiratory Disease
What do we know about the difference between secretory and systemic immunity and their effectiveness against CIRD?
The veterinary community shares many opinions about the use of vaccines that elicit secretory or systemic immune responses. The AAHA Canine Vaccine Guidelines state that both vaccines work; however for high-risk patients such as shelter or boarded dogs, mucosal protection is preferred.
Should veterinarians be concerned about single-antigen CIRD protection? What about canine parainfluenza, adenovirus or canine influenza as part of the CIRD complex?
It is well established that Bordetella bronchiseptica is the primary pathogen for CIRD. Dogs at high risk for CIRD may benefit from the broader coverage intranasal vaccines, such as BRONCHI-SHIELD III or NARAMUNE-2, and parenterally administered core vaccines, such as Duramune® Max 5. As for canine influenza, the disease has been identified in 20-plus states and licensed products are available should veterinarians want to protect their canine patients.